Hypothesis

We propose that luminal phosphate concentration in the renal proximal tubule is sensed by primary cilia through the polycystin‑2 (TRPP2) calcium channel, which modulates the activity of ADAM10/17 proteases governing the shedding of membrane‑bound α‑Klotho into the circulation. When phosphate is high, ciliary calcium influx suppresses ADAM-mediated Klotho shedding, reducing soluble Klotho while preserving membrane Klotho for FGF23 signaling. Chronic elevation of luminal phosphate (as occurs with high‑diet phosphate intake or early CKD) thus creates a state of renal tubular Klotho‑shedding deficiency despite normal or increased total Klotho expression, driving FGF23 resistance, compensatory FGF23 rise, and downstream Klotho‑independent FGFR4/FGFR1 pathogenic signaling in heart and lung.

Mechanistic Rationale

1. Cilia as Phosphate Sensors – Primary cilia in epithelial cells detect extracellular composition changes via mechanosensitive and ion channels. TRPP2, a cilia‑localized calcium channel, is known to respond to fluid flow and luminal solutes (1). We hypothesize that elevated phosphate directly or indirectly (via intracellular Na+/Pi cotransporter activity) augments TRPP2‑mediated Ca2+ spikes.

2. Calcium‑Dependent Protease Regulation – ADAM10 and ADAM17 shed the extracellular domain of Klotho; their activity is inhibited by elevated intracellular calcium through calmodulin‑dependent kinase pathways (3). Increased ciliary calcium would therefore diminish Klotho shedding, shifting the balance toward membrane‑bound Klotho.

3. FGF23 Resistance Loop – Membrane Klotho remains present but is insufficient to compensate for reduced soluble Klotho, which normally antagonizes IGF1R/PI3K/Akt and supports FOXO3 antioxidant signaling (4). The kidney retains FGF23 responsiveness (membrane Klotho as co‑receptor) but systemic Klotho loss removes its endocrine anti‑aging actions, prompting osteocytes to secrete more FGF23 to counteract perceived phosphate excess.

4. Pathogenic FGF23 Signaling – Persistent high FGF23, unable to effectively lower phosphate due to Klotho‑shedding deficit, engages Klotho‑independent FGFR4 in cardiomyocytes (PLC‑γ‑calcineurin‑NFAT hypertrophy) and FGFR1 in pulmonary arterial smooth muscle (vascular remodeling) (5,6).

Testable Predictions

• In vitro: Primary human renal proximal tubule cells cultured in high phosphate media will show increased TRPP2‑dependent calcium flux (measured with Fluo‑4 AM) and decreased soluble Klotho in the supernatant, without change in total Klotho protein or mRNA. Pharmacological blockade of TRPP2 (e.g., with ruthenium red) or chelation of intracellular calcium (BAPTA‑AM) will rescue Klotho shedding.

• In vivo: Mice fed a high‑phosphate diet (1.2% Pi) will develop elevated urinary calcium‑phosphate crystals, increased ciliary TRPP2 phosphorylation (p‑TRPP2), reduced plasma soluble Klotho, and elevated intact FGF23, preceding detectable vascular calcification. TrpP2 conditional knockout in renal tubules should abolish the phosphate‑induced decline in soluble Klotho and attenuate FGF23 rise and cardiac hypertrophy.

• Human Biomarker Study: In a cohort of early‑stage CKD patients, the ratio of urinary phosphorylated TRPP2 to soluble Klotho will positively correlate with plasma FGF23 and inversely correlate with estimated glomerular filtration rate (eGFR), independent of Klotho gene expression measured in peripheral blood mononuclear cells.

Falsifiability

If high luminal phosphate fails to alter TRPP2 activity or soluble Klotho shedding in renal tubules, or if manipulating TRPP2 does not affect the phosphate‑Klotho‑FGF23 axis as predicted, the hypothesis would be refuted. Likewise, if soluble Klotho levels remain unchanged despite genetic or pharmacologic disruption of ciliary calcium signaling in vivo, the proposed mechanistic link would be invalidated.

Broader Implications

Confirming this model would redefine early CKD pathogenesis as a ciliopathy‑driven endocrine dysregulation, suggesting that targeting renal ciliary calcium handling (e.g., with TRPP2 modulators) could preserve soluble Klotho homeostasis, break the FGF23‑positive feedback loop, and prevent cardiovascular and pulmonary complications before irreversible fibrosis sets in.